Total
0
Shares
Proteomics receives CE Mark for kidney disease test
  • Proteomics has secured CE Mark registration for its kidney disease test, PromarkerD
  • Promarker D is a simple blood test that uses a uniques protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear
  • This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population
  • Proteomics is up 1.49 per cent on the ASX and is selling shares for 34 cents apiece

Proteomics International Laboratories has secured CE Mark registration for its PromarkerD as a diagnostic medical device.

PromarkerD is a world-first test for predicting the beginning of diabetic kidney disease.

CE marking is a certification mark that indicates a fitting in with health, safety and environmental protection standards for products sold within the European Economic Area.

The test assesses the risk of diabetic kidney disease in patients with type 2 diabetes. Chronic kidney disease is one of the major complications that can come from diabetes and if unchecked can lead to dialysis or a kidney transplant.

Promarker D is a simple blood test that uses a unique protein 'fingerprint' to detect the disease up to four years before clinical symptoms appear.

"The CE Mark is another important milestone for PromarkerD as we move forward with new deals in the region," Managing Director Richard Lipscombe said.

"CE Mark registration reflects the strength of the clinical and technical data that we have collected in developing our ground-breaking test that could help save healthcare systems billions of dollars," he added.

This announcement follows the launch of PromarkerD in Spain, where diabetes affects 10 per cent of the adult population (3.6 million people).

The World Health Organisation believes that the European Region is home to 60 million adults with diabetes and currently 1 in 3 have chronic kidney disease.

"PromarkerD could aid clinical decision-making by identifying at-risk individuals for earlier therapeutic intervention and help to minimise the effect of the disease," the company stated.

Proteomics is up 1.49 per cent on the Australian Securities Exchange and is selling shares for 34 cents apiece at 12:55 pm AEDT.


Subscribe


PIQ by the numbers
More From The Market Herald
Bod Australia (ASX:BDA)- CEO, Jo Patterson - The Market Herald

" Bod Australia (ASX:BDA) receives R&D tax refund of $851k

Medicinal cannabis company Bod Australia (BDA) has received an $851,000 research & development (R&D) tax refund.
Medlab Clinical (ASX:MDC) - CEO, Dr Sean Hall - The Market Herald

" Medlab Clinical (ASX:MDC) completes NRGBiotic trial

Medlab Clinical (MDC) has completed the intervention stage of the Queensland University of Technology (QUT) depression trial using the NRGBiotic product.
Fiji Kava (ASX:FIJ) - Managing Director & CEO, Zane Yoshida - The Market Herald

" Fiji Kava (ASX:FIJ) reduces remuneration and board fees due to COVID-19

Health and wellness company, Fiji Kava (FIJ) has put in precautionary measures and protocols due to the coronavirus (COVID-19).
Creso Pharma (ASX:CPH) - Co founder, CEO & Executive Director, Dr Miri Halperin Wernli - The Market Herald

" Creso Pharma’s (ASX:CPH) subsidiary receives C$775K order from Israel

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a CA$775,000 purchase order for its medicinal cannabis flower from Univo Pharmaceuticals.